Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Retrovirology

Figure 2

From: The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G

Figure 2

Peptide 2 has an IC50 of 50 nM. MT2 cells were treated by Imquest BioSciences with varying doses of Peptide 2 in a spreading infection and infectivity assayed as described in Methods. The percent inhibition of viral infectivity by the peptide was determined during the first seven days of the spreading infection assay. The Inhibitor Concentration, IC (indicated within each histogram) was calculated relative to the untreated virus control.

Back to article page